Somatic defects in RAS, NF1, PTPN11, or CBL are detected in 85% of patients, evidencing RAS/MAPK-pathway (Rat Sarcoma virus /mitogen-activated protein kinase) activation as an important mechanism in JMML pathogenesis [92]. Here, PTPN11 is linked to juvenile myelomonocytic leukemia.